

PART I

Cadila Healthcare Limited

Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

	_					Unaudi	ted [Provisional] Financial Results for the Quarter and Six Months ended September 30, 2012	2.						
Rupees in Lacs CONSOLIDATED [Corresponding]							3 1 2 3 1 4 2 1 7 2 1 7		Rupees in Lacs					
					_						PANY			
3 Months	Preceding 3	3 months ended 30/09/2011 in	Year to date figures for the current period	Year to date figures for the previous year	Previous year	Sr. No	Particulars	3 Months	Preceding 3	3 months ended 30/09/2011 in	Year to date figures for the current period	Year to date figures for the		
ended 30/09/2012	months ended	the previous	ended	ended	ended			ended	months ended	the previous	ended	previous year ended	Previous yea ended	
(Unaudited)	30/06/2012 (Unaudited)	(Upaudited)	30/09/2012	30/09/2011	31/03/2012			30/09/2012	30/06/2012	year	30/09/2012	30/09/2011	31/03/2012	
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
154,469	154,664	122.007	200 422	242 777		1	Income from operations							
		123,887	309,133	242,777	518,067	1	Gross Sales	63,940	63,251	60,991	127,191	118,657	245,65	
3,219	3,054	1,923	6,273	3,462	9,070		Less: Excise Duty	1,617	1,122	929	2,739	1,904	4,32	
151,250	151,610	121,964	302,860	239,315	508,997		Net Sales	62,323	62,129	60,062	124,452	116,753	241,32	
3,514	7,832	1,676	11,346	8,894	17,334	b	Other operating income	17,161	20,993	16,989	38,154	38,485	73,753	
154,764	159,442	123,640	314,206	248,209	526,331	С	Total income from operations (net)	79,484	83,122	77,051	162,606	155,238	315,07	
			100000000000000000000000000000000000000	Secretary of	7	2	Expenses							
38,817	31,201	33,037	70,018	59,518	118,894	a	Cost of materials consumed	23,312	17,434	20,070	40,746	38,480	79,09	
22,700	17,101	11,678	39,801	27,707	67,852	b	Purchases of stock-in-trade	7,005	4,390	7,890	11,395	14,031	30,455	
(4,406)	3,034	(5,660)	(1,372)	(11,967)	(18,811)	С	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,617)	3,706	(2,309)	2,089	(3,323)	1	
22,830	22,976	18,935	45,806	35,858	75,122	d	Employee benefits expense	12,826	12,705	10,844	25,531	21,388	43,455	
4,323	4,343	3,754	8,666	7,226	15,788	e	Depreciation and amortisation expense	2,672	2,752	2,754	5,424	5,251	10,823	
51,760	49,389	41,943	101,149	83,147	174,888	f	Other expenses	28,409	24,615	24,630	53,024	49,694	101,145	
136,024	128,044	103,687	264,068	201,489	433,733	g	Total expenses	72,607	65,602	63,879	138,209	125,521	259,123	
18,740	31,398	19,953	50,138	46,720	92,598	3	Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	6,877	17,520	13,172	24,397	29,717	55,955	
646	951	1,104	1,597	1,735	5,315	4	Other income	5,202	269	15,410	5,471	16,275	23,914	
19,386	32,349	21,057	51,735	48,455	97,913	5	Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	12,079	17,789	28,582	29,868	45,992	79,869	
4,050	5,719	7,686	9,769	8,801	18,490	6	Finance costs	2,794	3,869	5,974	6,663	6,661	12,826	
15,336	26,630	13,371	41,966	39,654	79,423	7	Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	9,285	13,920	22,608	23,205	39,331	67,043	
0	0	0	0	0	0	8	Exceptional items	0	0	0	0	10,000	07,043	
15,336	26;630	13,371	41,966	39,654	79,423	9	Profit/ (Loss) from ordinary activities before tax (7+8)	9,285	13,920	22,608	23,205	39,331	67,043	
4,939	6,537	2,351	11,476	5,205	11,304	10	Tax expense	(460)	650	(490)	190	940	1,291	
10,397	20,093	11,020	30,490	34,449	68,119	11	Net Profit/ (Loss) from ordinary activities after tax (9-10)	9,745	13,270	23,098	23,015	38,391	65,752	
0	. 0	0	0	0	0	12	Extraordinary items (net of tax expense)	0	13,270	25,050	25,015	30,391	03,732	
10,397	20,093	11,020	30,490	34,449	68,119	13	Net Profit/ (Loss) for the period (11,12)	9,745	13,270	23,098	23,015	38,391	65,752	
0	0	0	0	0	0	14	Share of profit/ (loss) of associates	3,743	13,270	23,090	23,015	36,391	65,/52	
(883)	(614)	(752)	(1,497)	(1,199)	(2,860)	15	Minority interest	0	0		0		1	
9,514	19,479	10,268	28,993	33,250	65,259	16	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	9,745	13,270	23,098	23,015	38,391	65,752	
10,237	10,237	10,237	10.227	10.227	40.227						23,015	30,391	05,/52	
10,237	10,237	10,237	10,237	10,237	10,237	17	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237	10,237	10,237	
				-	247,122	18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						244,695	
						19 i	Earnings per share (before extraordinary items)	1		-				
4.65	0.54	F 04		46.51			(of Rs. 5/- each) (not annualised):							
	9.51	5.01	14.16	16.24	31.87		Basic (Rs.)	4.76	6.48	11.28	11.24	18.75	32.11	
4.65	9.51	5.01	14.16	16.24	31.87		Diluted (Rs.)	4.76	6.48	11.28	11.24	18.75	32.11	
						19 ii	Earnings per share (after extraordinary items)				0.000			

4.76

6.48

11.28

11.24

18.75

32.11

32.11

Notes

4.65

4.65

9.51

[1] The above results for the quarter/ six months ended on September 30, 2012 were reviewed by the Audit Committee on November 6, 2012 and then approved by the Board of Directors at their meeting held on November 7, 2012.

Basic (Rs.)

(of Rs. 5/- each) (not annualised):

[2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Clause 41 of the Listing Agreement.

16.24

16.24

- During the quarter, Finest Procuring Solutions Limited, a step down subsidiary merged with Zydus Animal Health Limited, a wholly owned subsidiary of the Company with effect from August 27, 2012 pursuant to a Scheme of Amalgamation approved by the Delhi High Court.
- [4] The company has incorporated Hercon Pharmaceuticals LLC as a wholly owned subsidiary of Zydus Noveltech Inc. USA and has invested an initial capital of USD 100,000.

31.87

31.87

- [5] The changes in Investments during the quarter are as under:
 - Zydus BSV Pharma Private Limited [Additional Investment] Rs. 200 Lacs

14.16

Zydus Lanka Private Limited, Sri Lanka - Rs. 4 Lacs

5.01

[6] The above financial results include loss on account of foreign exchange fluctuations of Rs. 4,909 Lacs for the quarter [loss of Rs. 7,752 Lacs in the corresponding quarter of previous year] on standalone basis and Rs. 7,565 Lacs for the quarter [loss of Rs. 7,202 Lacs in the corresponding quarter of previous year] on consolidated basis.

The above financial results include loss on account of foreign exchange fluctuations of Rs. 5,746 Lacs for the six months [loss of Rs. 6,837 Lacs in the corresponding six months of previous year] on standalone basis and Rs. 5,884 Lacs for the six months [loss of Rs. 5,266 Lacs in the corresponding six months of previous year] on consolidated basis.

- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the current reporting period.
- [8] The Company has one segment of activity viz., "Pharmaceuticals".

PART II													
							Select information for the Quarter and Six Months ended 30/09/2012						
		Corresponding								Corresponding			
		3 months	Year to date	Year to date						3 months	Year to date	Year to date	
		ended	figures for the	figures for the			Particulars				figures for the		
3 Months	Preceding 3	30/09/2011 in	current period	previous year	Previous year		Particulars	3 Months	Preceding 3		current period		Previous year
ended	months ended	the previous	ended	ended	ended			ended	months ended	the previous	ended	ended	ended
30/09/2012	30/06/2012	year	30/09/2012	30/09/2011	31/03/2012	2		30/09/2012	30/06/2012	year	30/09/2012	30/09/2011	31/03/2012
						A	PARTICULARS OF SHAREHOLDING						1
						1	Public shareholding					Total Control	
51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474		- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474
25.21%	25.21%	25.21%	25.21%	25.21%	25.21%		- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%	25.21%	25.21%
						2	Promoters and Promoter Group Shareholding						
						7.00	and the short						4

- Percentage of shares (as a % of the total shareholding of promoter and promoter group)

- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)

- Percentage of shares (as a % of the total share capital of the company)

- Percentage of shares (as a % of the total share capital of the company)

- Number of shares

- Number of shares

Non - encumbered

N.A.

N.A.

100.00%

74.79%

153,138,046 153,138,046

100.00%

74.79%

153,138,046 153,138,046

100.00%

74.79%

100.00%

74.79%

	Particulars		3 months ended 30/09/2012
В	INVESTOR COMPLAINTS [In Numbers]		
	Pending at the beginning of the quarter		Nil
	Received during the quarter		11
	Disposed of during the quarter		11
	Remaining unresolved at the end of the guarter		Nil

Nil N.A. N.A.

153,138,046

100.00%

74.79%

153,138,046

100.00%

74.79%

N.A.

153,138,046

100.00%

74.79%

N.A.

153,138,046

100.00%

74.79%

N.A.

153,138,046

100.00%

74.79%

N.A.

153,138,046

100.00%

74.79%

CONSOL	IDATED		COMI	COMPANY Rupees in Lacs			
Rupees	in Lacs		Rupees				
As at current half year end 30/09/2012 (Unaudited)	As at previous year end 31/03/2012 (Audited)	Particulars	As at current half year end 30/09/2012 (Unaudited)	As at previo year end 31/03/201 (Audited)			
6	12%	EQUITY AND LIABILITIES					
		1 Shareholders' funds					
10,237	10,237	a Share capital	10,237	10,2			
277,560	247,122	b Reserves and surplus	269,683	244,6			
0	0	c Money received against share warrants	0				
287,797	257,359	Sub-total - Shareholders' funds	279,920	254,9			
0	0	2 Share application money pending allotment	. 0				
10,548	9,043	3 Minority Interest	0				
1000		4 Non-current liabilities					
121,912	132,234	a Long-term borrowings	59,306	68,4			
11,918	11,846	b Deferred tax liabilities (net)	12,674	12,4			
5,054	4,260	c Other long-term liabilities	2,681	1,9			
7,150	7,562	d Long-term provisions	4,584	4,7			
146,034	155,902	Sub-total - Non-current liabilities	79,245	87,6			
140,034	100,502	5 Current liabilities					
98,839	68,710	a Short-term borrowings	70,356	41,1			
63,846	54,551	b Trade payables	39,378	28,4			
1000	95.00.000	c Other current liabilities	40,838	41,0			
80,098	69,243	d Short-term provisions	698	17,9			
9,161	22,805			128,5			
251,944	215,309	Sub-total - Current liabilities 6 Foreign Currency Monetary Translation Difference Account	151,270 540	7			
0	311	Foreign Currency Monetary Items Translation Difference Account TOTAL - EQUITY AND LIABILITES					
696,323	637,924		510,975	471,9			
30		The state of the s					
		1 Non-current assets					
265,591	234,382	a Fixed assets	179,199	152,9			
98,802	98,802	b Goodwill on consolidation	0				
2,115	2,115	C Non-current investments	110,259	110,2			
30,202	26,313	d Long-term loans and advances	59,787	56,5			
0	0	e Other non-current assets	0				
396,710	361,612	Sub-total - Non-current assets	349,245	319,7			
		2 Current assets					
3,584	304	a Current investments	6,642	10,9			
111,651	109,050	b Inventories	48,789	50,1			
100,181	88,631	C Trade receivables	67,247	58,1			
50,456	46,662	d Cash and cash equivalents	14,756	11,8			
27,613	27,458	e Short-term loans and advances	20,873	19,1			
5,612	4,207	f Other current assets	3,423	1,9			
299,097	276,312	Sub-total - Current assets	161,730	152,1			
516	2/0,312	3 Foreign Currency Monetary Items Translation Difference Account	0	104/1			
		TOTAL - ASSETS	510,975	471,91			
696,323	637,924	Total Assets	510,975	7/1,9			

Pankaj R. Patel
Chairman & Managing Director

Ahmedabad, November 7, 2012

153,138,046

100.00%

74.79%

153,138,046

100.00%

74.79%